Paperpal Prime Logo

American Journal of Hematology : Impact Factor & More

eISSN: 1096-8652pISSN: 0361-8609

Aims and Scope of American Journal of Hematology

American Journal of Hematology is an academic journal devoted to the coverage of blood diseases. It has been published since 1976.

Key Metrics

CiteScore
13.4
Eigenfactor
0.01 - 0.05
H-Index
121
Impact Factor
10 - 15
Scite Index
0.88 5-Year SI
SJR
Q1Hematology
SNIP
2.9
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on American Journal of Hematology

American Journal of Hematology Journal Specifications

Overview
Publisher WILEY
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1976
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in American Journal of Hematology ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in American Journal of Hematology

Extended Cancer Spectrum in Adults With Telomere Biology Disorders: Insights From a 113-Patient Single-Center Cohort.
  • 1 Sep 2026
  • American journal of hematology
Defining a Subgroup of Myelodysplastic Syndrome Patients With Very Poor-Risk Cytogenetics Demonstrating a Relatively More Favorable Outcome After Allogeneic Hematopoietic Cell Transplantation.
  • 1 Sep 2026
  • American journal of hematology
Dexamethasone for Management of Cytokine Release Syndrome Associated With Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma.
  • 1 Sep 2026
  • American journal of hematology
EIF2AK1 As a Key Genetic Determinant of Luspatercept Resistance in Transfusion-Dependent Thalassemia.
  • 1 Sep 2026
  • American journal of hematology
Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.
  • 1 Sep 2026
  • American journal of hematology
Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in1st Line Mantle Cell Lymphoma.
  • 1 Sep 2026
  • American journal of hematology
Extended Cancer Spectrum in Adults With Telomere Biology Disorders: Insights From a 113-Patient Single-Center Cohort.
  • 1 Sep 2026
  • American journal of hematology
Defining a Subgroup of Myelodysplastic Syndrome Patients With Very Poor-Risk Cytogenetics Demonstrating a Relatively More Favorable Outcome After Allogeneic Hematopoietic Cell Transplantation.
  • 1 Sep 2026
  • American journal of hematology
Dexamethasone for Management of Cytokine Release Syndrome Associated With Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma.
  • 1 Sep 2026
  • American journal of hematology
EIF2AK1 As a Key Genetic Determinant of Luspatercept Resistance in Transfusion-Dependent Thalassemia.
  • 1 Sep 2026
  • American journal of hematology
Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.
  • 1 Sep 2026
  • American journal of hematology
Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in1st Line Mantle Cell Lymphoma.
  • 1 Sep 2026
  • American journal of hematology

FAQs on American Journal of Hematology